The market of biologics is growing at a nearly twice the rate of pharma as a whole. Biologics are expected to account for approximately 17% of total global spending on medicines by 2016, and reach an overall market value of $200 billion to $210 billion in 2016, up from $157 billion in 2011. Seven of the top 10 global medicines by spending will be a biologic within the next 5 years.
Our collaborative, cross-functional team develops tailored, cost-effective services to meet the unique needs of biosimilars clinical development.
A core aspect of the drug development landscape has been and always will be an intimate expertise in therapeutic areas. Our experts will partner with…
Biosimilars Fact Sheet
Biosimilar drug development is unique and complex. At PRA, our cross-functional team of experts guide you through the many nuances of the biosimilar…